Articles Tagged With:
-
Oral Progestogens for Prevention of Miscarriage
In this double-blind, randomized clinical trial, 406 pregnant women were randomized to dydrogesterone or placebo. There were no statistically significant differences in the primary outcome (miscarriage before 20 weeks of gestation; relative risk, 0.897; 95% confidence interval, 0.548-1.467; P = 0.772), which occurred in 12.8% and 14.3% in the dydrogesterone and placebo arms, respectively. The use of dydrogesterone in women with threatened miscarriage for the prevention of early pregnancy loss in the first trimester failed to decrease the miscarriage rate or increase the live birth rate.
-
Is HPV Testing Superior to Pap Testing Alone in Women at Risk of Cervical Cancer?
In this registry-based screening study of women in Catalonia, Spain, a negative human papillomavirus (HPV) and cytology co-test at baseline was associated with a cumulative incidence of cervical precancer of 0.4% at five years and 1.3% at nine years, compared to 27% among women with abnormal HPV testing at baseline.
-
Pregnancy After Treatment for Pelvic Floor Disorders
This consensus document was developed as a reference for physicians caring for and advising women in pregnancy following prior surgical treatment for pelvic floor disorders.
-
The Pregnancy Perspective: What Has COVID-19 Affected?
In this cross-sectional descriptive study, women using the Ovia pregnancy app expressed receiving adequately safe maternal care during the COVID-19 pandemic, but voiced concerns related to obtaining infant supplies and prenatal education.
-
OCR Audit Findings Show Where to Focus HIPAA Compliance
Implementing a good security program with risk analysis, security practices, and risk mitigation can be a safe harbor from penalties.
-
Lessons Learned from Overturned $4.3 Million HIPAA Penalty
A covered entity’s victory over proposed penalties from the Department of Health and Human Services was good news for those responsible for HIPAA compliance, showing that good faith efforts and a willingness to fight the allegations can pay off.
-
Revenue Cycle Staff Needs Education on Cures Act
Starting April 5, patients must be able to access all the health information in their electronic medical records without delay, as required by the ONC Cures Act Final Rule. Most organizations will be able to leverage their existing technology to make records available to patients. Revenue cycle departments will need to review scripting to ensure it aligns with the new rules.
-
The Mystery of COVID-19’s Financial Impact
The revenue cycle impact is going to vary, depending on many factors. Short- and long-term evaluations of the COVID-19 pandemic impact are necessary to make sound conclusions and determine any future actions/directions.
-
COVID-19-Specific Codes Can Maximize Reimbursement
As many hospitals continue managing COVID-19 patients, six new ICD-10 codes will help facilities obtain reimbursement.
-
Coping with Aftermath of COVID-19 Reimbursement Changes
Health plans issued many waivers during COVID-19 — for authorizations, for copays, and for telehealth. But patient access departments soon found the devil was in the details, with varying time frames and stipulations all coming into play. The result: A flood of denied claims. Learn how registrars are starting to sort through the mess.